TAKEDA PHARMA A/S - CVR: 16406899

2022, DKK

29.09.2023

Bruttoresultat

121''

Primær drift

20.842'

Årets resultat

13.573'

Aktiver

486''

Kortfristede aktiver

410''

Egenkapital

94.892'

Afkastningsgrad

4 %

Soliditetsgrad

20 %

Likviditetsgrad

109 %

Resultat

29.09.2023

Årsrapport	2022 29.09.2023	2021 28.09.2022	2020 14.09.2021	2019 04.12.2020	2018 09.09.2019	2017 30.08.2018	2016 30.08.2017	2015 31.08.2016
Nettoomsætning	1.061.206.000	910.058.000	1.939.231.000	1.569.593.000	1.571.272.000	1.782.339.000	1.728.098.000	1.682.747.000
Bruttoresultat	120.582.000	153.989.000	1.134.904.000	3.183.667.000	562.304.000	712.119.000	625.966.000	212.494.000
Resultat af primær drift	20.842.000	41.266.000	952.860.000	3.005.650.000	257.444.000	531.192.000	454.331.000	29.389.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	543.000	2.372.000	428.000	15.065.000	0	7.816.000	24.049.000	196.100.000
Finansieringsomkostninger	-533.000	-917.000	-39.567.000	-3.883.000	-947.000	159.245.000	-528.073.000	-1.742.291.000
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	20.852.000	42.721.000	913.721.000	3.311.294.000	84.741.454.000	714.099.000	-24.071.000	25.316.933.000
Resultat	13.573.000	31.795.000	667.744.000	2.661.113.000	84.680.112.000	595.839.000	-102.646.000	25.296.957.000
Forslag til udbytte	0	0	-1.000.000.000	-2.300.000.000	-1.300.000.000	0	0	0

Aktiver

29.09.2023

Årsrapport	2022 29.09.2023	2021 28.09.2022	2020 14.09.2021	2019 04.12.2020	2018 09.09.2019	2017 30.08.2018	2016 30.08.2017	2015 31.08.2016
Kortfristede varebeholdninger	138.994.000	40.360.000	85.321.000	98.636.000	67.283.000	76.833.000	88.943.000	73.073.000
Kortfristede tilgodehavender fra salg og tjenesteydelser	271.240.000	514.068.000	1.863.593.000	3.578.492.000	1.152.686.000	2.383.799.000	2.236.384.000	2.510.140.000
Likvider	2.000	2.143.000	2.172.000	2.000	76.514.000	2.000	2.000	1.000
Kortfristede aktiver	410.236.000	556.571.000	1.951.086.000	3.677.130.000	1.296.483.000	2.460.634.000	2.325.329.000	2.583.214.000
Immaterielle aktiver og goodwill	1.443.000	1.395.000	2.010.000	9.085.000	15.117.000	45.354.000	30.469.000	60.418.000
Finansielle anlægsaktiver	31.200.000	19.334.000	13.576.000	2.884.000	171.996.000	98.281.883.000	97.913.882.000	98.202.447.000
Materielle aktiver	42.871.000	44.993.000	50.348.000	113.321.000	63.355.000	94.194.000	117.326.000	119.635.000
Langfristede aktiver	75.514.000	65.722.000	65.934.000	125.290.000	250.468.000	98.421.431.000	98.061.677.000	98.382.500.000
Aktiver	485.750.000	622.293.000	2.017.020.000	3.802.420.000	1.546.951.000	100.882.065.000	100.387.006.000	100.965.714.000

Aktiver

29.09.2023

Passiver

29.09.2023

Årsrapport	2022 29.09.2023	2021 28.09.2022	2020 14.09.2021	2019 04.12.2020	2018 09.09.2019	2017 30.08.2018	2016 30.08.2017	2015 31.08.2016
Forslag til udbytte	0	0	1.000.000.000	2.300.000.000	1.300.000.000	0	0	0
Egenkapital	94.892.000	81.238.000	1.046.401.000	2.707.245.000	1.314.274.000	100.534.993.000	99.939.154.000	100.236.684.000
Hensatte forpligtelser	2.927.000	1.239.000	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld		584.000	1.264.000	1.146.000	1.811.000	905.000	765.000	812.000
Leverandører af varer og tjenesteydelser	25.356.000	16.704.000	54.624.000	67.791.000	55.941.000	59.994.000	80.330.000	57.192.000
Kortfristede forpligtelser	375.272.000	525.597.000	952.485.000	1.061.868.000	230.866.000	287.981.000	377.056.000	646.343.000
Gældsforpligtelser	387.931.000	539.816.000	970.619.000	1.095.175.000	232.677.000	347.072.000	447.852.000	729.030.000
Forpligtelser	387.931.000	539.816.000	970.619.000	1.095.175.000	232.677.000	347.072.000	447.852.000	729.030.000
Passiver	485.750.000	622.293.000	2.017.020.000	3.802.420.000	1.546.951.000	100.882.065.000	100.387.006.000	100.965.714.000

Passiver

29.09.2023

Nøgletal

29.09.2023

Årsrapport	2022 29.09.2023	2021 28.09.2022	2020 14.09.2021	2019 04.12.2020	2018 09.09.2019	2017 30.08.2018	2016 30.08.2017	2015 31.08.2016
Afkastningsgrad	4,3 %	6,6 %	47,2 %	79,0 %	16,6 %	0,5 %	0,5 %	0,0 %
Dækningsgrad	11,4 %	16,9 %	58,5 %	202,8 %	35,8 %	40,0 %	36,2 %	12,6 %
Resultatgrad	1,3 %	3,5 %	34,4 %	169,5 %	5.389,3 %	33,4 %	-5,9 %	1.503,3 %
Varelagerets omsætningshastighed	7,6	22,5	22,7	15,9	23,4	23,2	19,4	23,0
Egenkapitals-forretning	14,3 %	39,1 %	63,8 %	98,3 %	6.443,1 %	0,6 %	-0,1 %	25,2 %
Payout-ratio	Na.	Na.	149,8 %	86,4 %	1,5 %	Na.	Na.	Na.
Gældsdæknings-nøgletal	3.910,3 %	4.500,1 %	2.408,2 %	77.405,4 %	27.185,2 %	-333,6 %	86,0 %	1,7 %
Soliditestgrad	19,5 %	13,1 %	51,9 %	71,2 %	85,0 %	99,7 %	99,6 %	99,3 %
Likviditetsgrad	109,3 %	105,9 %	204,8 %	346,3 %	561,6 %	854,4 %	616,7 %	399,7 %

Resultat

29.09.2023

Gæld

29.09.2023

Årsrapport

29.09.2023

Nyeste:01.04.2022- 31.03.2023(offentliggjort: 29.09.2023)

Information om virksomhedens regnskabsklasse:The Annual Report of Takeda Pharma A/S for FY 2021/22 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to large enterprises of reporting class C . The accounting policies applied remain unchanged from last year. The Financial Statements for 2021/22 are presented in DKK'000.

Beretning

29.09.2023

Dato for ledelsens godkendelse af årsrapporten:2023-09-19

Ledelsespåtegning:Ledelsespåtegning

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainty relating to recognition and measurementRecognition and measurement in the Annual Report have not been subject to any uncertainty.

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual eventsThe outbreak of COVID-19 escalated in early 2020, and on March 11, 2020, the WHO declared the outbreak a worldwide pandemic. Takeda Pharma A/S has not been negatively impacted by the pandemic. The company has participated in delivering to the national emergency stock and not been significantly exposed to Covid-19 related out of stock. For further information please refer to note 1. Takeda Pharma A/S has declined to receive any support from the society during the pandemic as the company has not been directly impacted.

Oplysning om usædvanlige forhold:NoterUnusual eventsDuring the financial year 2022/23 and up to the date of this report Takeda Pharma A/S has carried out its business operations as normal without any negative impact of the Covid-19 pandemic however had less travel activities than in a normal year. We have so far not seen any shortages on supply due to the pandemic and are not exposed to Russia or Ukraine.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Takeda Pharma A/S for the financial year 1 April 2022 - 31 March 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Key activitiesTakeda Pharma A/S is the operating company for the local activities in Denmark and a few group related activities. The Company is part of the Japanese pharmaceutical company Takeda Pharmaceutical Company Limited. During 2021/22 the activities in Takeda Pharma A/S were primarily related to local marketing activities as the former production unit and selected products were divested as per end of fiscal year 2019/20. The marketing activities in Denmark include sale, marketing and registration for the Danish market. After divestments Takeda in Denmark has a product portfolio within Inflammatory bowel disease, Neuroscience, Rare Diseases, Plasma Derived Therapies and Oncology.